Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance

NCT02593331 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02593331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02593331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2015
Completion date
March 28, 2017
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insulin resistance